Vitamin C (ascorbate/ascorbic acid) is a water-soluble molecule that is essential for life. Ascorbate is a cofactor for copper-dependent monooxygenases (such as dopamine-β-hydroxylase) and iron-dependent dioxygenases (such as collagen prolyl and lysyl hydroxylases). It is also an antioxidant that prevents cellular damage from oxygen radicals. Most vertebrates satisfy their need for ascorbate by synthesizing it de novo from glucose, but some mammals including humans have lost this ability and must obtain vitamin C from their diets. Vitamin C deficiency leads to a disease called scurvy, first described by Hippocrates, which is characterized by liver spots on the skin, gingival hyperplasia, and bleeding from mucous membranes. For the rare mammalian species that do not synthesize vitamin C, ascorbate and its oxidized form dehydroascorbate (DHA) are taken up from the diet and carried in the plasma to cells throughout the body (Rose, 1988) . Cells then readily reduce DHA to ascorbate. Many cells have high-affinity transporters for vitamin C, but mature red blood cells (RBCs) do not have these transporters and cannot take up vitamin C from plasma (May, 1998) . In this issue, Montel-Hagen et al. (2008) demonstrate that the glucose transporter Glut1 of mature human RBCs enables efficient uptake of DHA by these cells. They then determined that there is a switch in Glut1 substrate specificity from glucose to DHA that is regulated by stomatin, a membrane protein that binds to Glut1. The switch in substrate affinity of Glut1 is a unique feature of those mammals that are incapable of de novo synthesis of vitamin C.
It is well established that DHA is a substrate for the glucose transporter Glut1 and competes with glucose, albeit weakly, for transport by ectopically expressed Glut1 (Rose, 1988; Bianchi and Rose, 1986; Vera et al., 1993) (Figure 1 ). Montel-Hagen et al. (2008) now report that mature human RBCs, unlike erythrocytes from most species, express very high levels of Glut1. They observe that whereas Glut1 expression increases during erythrocyte differentiation, paradoxically, the rate of glucose transport decreases. In contrast, the rate of DHA uptake increases dramatically with RBC differentiation, and glucose is no longer a competitive substrate for transport. In considering how the substrate affinity of Glut1 could be affected, the authors capitalized on the knowledge that the membrane protein stomatin is a Glut1-binding protein and when ectopically expressed reduces the affinity of Glut1 for glucose (Zhang et al., 2001 ). Montel-Hagen and colleagues extend this observation by showing that expression of stomatin increases the affinity of Glut1 for DHA and reduced the ability of glucose to compete with DHA. The investigators also showed that expression of stomatin, like Glut1, increases during differentiation of RBCs. Humans with a rare genetic disease (overhydrated heredi-Most vertebrates synthesize vitamin C (ascorbate) de novo from glucose, but humans and certain other mammals cannot. In this issue, Montel-Hagen et al. (2008) demonstrate that erythrocytes from these ascorbate auxotrophs switch the preference of their glucose transporter Glut1 from glucose to dehydroascorbate (DHA), the oxidized form of vitamin C. This substrate preference switch is mediated by the membrane protein stomatin and is an evolutionary adaptation to vitamin C deficiency. Most mammals are capable of de novo synthesis of vitamin C (ascorbic acid) from glucose, which is taken up by transporters of the Glut family, Glut1 or Glut4, expressed by red blood cells (RBCs). In humans and certain other mammals incapable of de novo vitamin C synthesis, the affinity of glucose and another vitamin C precursor called dehydroascorbate (DHA) for the transporter Glut1 is altered by the membrane protein stomatin. Immature human RBCs express Glut1 and primarily take up glucose in preference to DHA. During RBC differentiation, expression of stomatin increases. Stomatin binds to Glut1 and changes its substrate preference from glucose to DHA. Within RBCs, DHA is then reduced to ascorbic acid and is released back into plasma thus increasing the plasma concentration of vitamin C. tary stomatocytosis) produce too little stomatin. Montel-Hagen et al. found that RBCs from these patients have higher rates of glucose transport and lower rates of DHA transport than wildtype cells, confirming the role of stomatin in modulating DHA uptake.
Humans are part of a select group of vertebrates that have lost the ability to synthesize ascorbic acid. Other ascorbic acid "auxotrophs" include the Haplorrhini suborder of primates (New World monkeys, Old World monkeys and apes), guinea pigs, and fruit bats. Montel-Hagen and coworkers demonstrate that mature RBCs of these ascorbate auxotrophs express high levels of Glut1 and have correspondingly high rates of DHA uptake. Mature RBCs from animals that are able to synthesize ascorbic acid (including lemurs) take up smaller amounts of DHA. The authors conclude that stomatin, by binding to Glut1, enables the mature RBCs of ascorbic acid auxotrophs to take up DHA, which then can be converted into ascorbic acid. The increased expression of Glut1 by mature RBCs appears to be an adaptive response to the loss of de novo ascorbic acid synthesis.
In humans, other members of the Haplorrhini primate subgroup, and guinea pigs, the inability to synthesize ascorbic acid is due to mutations in the enzyme L-gulono-γ-lactone oxidase (GLO) that result in its inactivation. The inactivating event in guinea pigs is relatively recent (20 million years) and occurred after this species diverged from other vertebrates (Nishikimi et al., 1992) . It is not clear when fruit bats lost the ability to synthesize vitamin C, but that too is due to inactivation of GLO. Each of these species has responded by increasing the uptake of DHA by RBCs through increased expression of Glut1. What has not been shown, but is inferred, is that enhanced DHA uptake is due to an interaction between Glut1 and stomatin. Did this evolutionary solution to vitamin C deficiency occur independently three times (primates, guinea pigs, and fruit bats)? Or is stomatin-altered Glut1 activity also a conserved feature of the tissues (but not RBCs) from vertebrates capable of synthesizing ascorbic acid?
DHA is efficiently recycled to vitamin C within RBCs (and other cells) even though RBCs do not have the dioxygenase enzymes for which vitamin C serves as a cofactor (Arrigoni and De Tullio, 2002) . Vitamin C may have an antioxidant effect on erythrocyte membranes, as one of the symptoms of scurvy is decreased RBC life span. In contrast to species capable of de novo vitamin C synthesis, mature RBCs of species that cannot synthesize vitamin C are likely to be an important source of vitamin C in plasma (May, 1998) . Vitamin C does not seem to accumulate in RBCs, as the level of cytosolic ascorbic acid is similar to that in plasma. These data suggest that vitamin C is efficiently excreted by RBCs into plasma where it acts as an antioxidant preventing peroxidation of plasma lipoproteins (Frei et al., 1990 ) and also as a source of vitamin C for other cell types.
Vitamin C has had a colorful history as a therapeutic agent. The authors point out the interesting fact that many of the recommended vitamin C daily requirements were determined using mice and rats with an inactivated GLO enzyme. The amount of vitamin C required to alleviate symptoms of scurvy is much higher than the levels found in humans (Pauling, 1970) . This difference might be the result of the ability of human RBC Glut1 to accumulate and convert DHA to ascorbic acid. Recommended doses of vitamin C for humans may be excessive, as they do not take into account this evolutionary adaptation to ascorbic acid deficiency.
